Search clinical trials for: Remission High-Risk Neuroblastoma

Total 2248 results

Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Completed

A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma

Neuroblastoma

United States
Giselle Sholler
Beat NB Cancer Foundation; Because of Ezra; K C Pharmaceuticals Inc.

Completed

Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission

Neuroblastoma

United States
Y-mAbs Therapeutics

Withdrawn

Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.

Neuroblastoma

Korea, Republic of, Singapore, Hong Kong, Russian Federation
Memorial Sloan Kettering Cancer Center

Terminated

3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center

Completed

3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma

Neuroblastoma

United States

This is a preview

Log in or create a free account to see all matching trials and use the full search.

Log in Register

Subscribe